儿童 COVID-19 门诊患者接受卡司瑞韦单抗和伊德维单抗（CAS+IMD）的安全性和药代动力学。
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.
作者信息
Norton Thomas D, Thakur Mazhar, Ganguly Samit, Ali Shazia, Chao Jesse, Waldron Alpana, Xiao Jing, Turner Kenneth C, Davis John D, Irvin Susan C, Pan Cynthia, Atmodjo Dominique, Hooper Andrea T, Hamilton Jennifer D, Hussein Mohamed, Subramaniam Danise, Roque-Guerrero Lilia, Kohli Anita, Mylonakis Eleftherios, Geba Gregory P, Cox Edward, Braunstein Ned, Dakin Paula, Kowal Bari, Bhore Rafia, DiCioccio A Thomas, Hughes Diana, Herman Gary A
机构信息
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Bio-Medical Research, Miami, Florida, USA.
出版信息
J Pediatric Infect Dis Soc. 2024 Nov 27;13(11):589-593. doi: 10.1093/jpids/piae105.
The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.
在一项针对儿童 2019 冠状病毒病（COVID-19）门诊患者的随机 1/2/3 期试验中评估了 casirivimab + imdevimab（CAS + IMD）（抗严重急性呼吸综合征冠状病毒 2 [SARS-CoV-2] 单克隆抗体 [mAb]）的安全性。与成人一致，CAS + IMD 通常具有良好的耐受性，药物诱导的免疫原性发生率较低。这些发现支持开发针对高危儿科患者的下一代抗 SARS-CoV-2 mAb。
Zotero 插件